Syndax Pharmaceuticals, Inc.
SNDX
$11.05
-$0.28-2.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -38.56% | 257.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -38.56% | 257.14% | |||
| Cost of Revenue | 23.99% | 46.80% | |||
| Gross Profit | -38.86% | -28.77% | |||
| SG&A Expenses | 21.17% | 7.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.93% | 31.35% | |||
| Operating Income | -7.58% | -20.70% | |||
| Income Before Tax | -11.94% | -23.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.94% | -23.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.94% | -23.60% | |||
| EBIT | -7.58% | -20.70% | |||
| EBITDA | -7.58% | -20.70% | |||
| EPS Basic | -11.48% | -23.37% | |||
| Normalized Basic EPS | -11.47% | -23.35% | |||
| EPS Diluted | -11.48% | -23.37% | |||
| Normalized Diluted EPS | -11.47% | -23.35% | |||
| Average Basic Shares Outstanding | 0.42% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.42% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||